Digestine

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Digestine

Quick Facts

Property Description
Active ingredient Metoclopramide
Form Tablet, Oral solution, Injection
Pharmacological class Dopamine Receptor Antagonist, Prokinetic Agent
General purpose Relieves nausea and vomiting, enhances gastrointestinal movement
Origin Synthetic, Substituted Benzamide Derivative

What Type of Medicine is Digestine? (Classification and Origin)

Digestine is the trade name for a prescription-only synthetic drug containing the active ingredient Metoclopramide, which is classified fundamentally as a Dopamine-2 (D2) Antagonist and an Anti-emetic Agent. This substance is a synthetic compound derived from the substituted benzamide chemical class.

The drug's dual classification is essential to its function; as a Prokinetic Agent, it specifically addresses issues related to movement, while as an Anti-emetic Agent, it works to prevent nausea and vomiting. Metoclopramide is an established pharmaceutical, known for its clinical utility.

Composition and Available Forms of Digestine

The medicine is a single-ingredient product, featuring Metoclopramide (as the hydrochloride salt) as its sole therapeutic compound. Digestine is offered in various dosage forms to accommodate patient needs, including conventional oral tablets and an oral solution (or syrup) for ingestion, particularly beneficial for patients with difficulty swallowing. It is also available as a sterile liquid solution for injection, utilized for parenteral delivery in acute clinical settings.

General Purpose and Physiological Role of this Gastrointestinal Agent

The overarching goal of Digestine is to relieve the symptoms of nausea and vomiting and to normalize the function of the upper digestive system. Its primary mechanism allows it to accelerate the movement of contents out of the stomach. This function is beneficial in typical use scenarios involving conditions where the stomach empties too slowly. The integrated action of the drug on both central neurological signals and peripheral muscle movement makes it a robust gastrointestinal agent, specifically designed to address both the feelings of illness and the underlying physical issue of sluggish movement.

Regulatory References

  1. here

What side effects are possible with Digestine?

Possible Side Effects and Safety Information

The safety profile of Digestine (metoclopramide) is structured around potential adverse reactions affecting multiple physiological systems, primarily the nervous system and gastrointestinal tract, as documented in official regulatory labeling.

Officially Documented Adverse Reactions

The most frequently reported side effect is somnolence (drowsiness or sleepiness), which is officially classified as Very Common. Other reactions classified as Common include diarrhea, asthenia (fatigue), hypotension, and disorders related to movement, such as Parkinsonism and Akathisia (restlessness).

Adverse reactions are grouped by System-Organ-Class (SOC) in regulatory documents, including:

  • Nervous System Disorders: Includes Extrapyramidal Disorders (EPS) and sedation.
  • Cardiac Disorders: Such as bradycardia (slow heart rate) and, rarely, serious events like cardiac arrest and QT prolongation.
  • Psychiatric Disorders: Including depression and hallucinations.

Serious Safety Considerations and Duration Constraints

The official labeling notes the risk of serious but rare reactions. The most significant is Tardive Dyskinesia (TD), a potentially irreversible movement disorder. The risk of TD is specifically linked to the duration of treatment and the total cumulative dose. Consequently, regulatory documents restrict the typical duration of treatment to a maximum of 12 weeks or 3 months.

Serious, acute reactions such as Neuroleptic Malignant Syndrome (NMS) and severe forms of Extrapyramidal Disorders (like dystonia) can occur, often shortly after initiating treatment or after a single dose.

Population-Specific Safety Notes

The safety profile includes specific notes for certain patient groups. Official documents highlight an increased risk of Extrapyramidal Disorders in the pediatric population. Additionally, dose adjustments are required for patients with documented severe renal or hepatic impairment due to altered drug clearance. The medicine is contraindicated in specific clinical scenarios, including gastrointestinal hemorrhage, mechanical obstruction, or perforation.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the manifestations of Metoclopramide (Digestine) overdosage and the required emergency response.


Documented Overdose Presentations

Overdosage typically presents with drowsiness, confusion, disorientation, and extrapyramidal reactions (involuntary movements), which can include acute dystonia, neck spasms, and facial grimacing. Convulsive seizures are also explicitly documented in regulatory sources as a risk associated with overdosage.


Severe Outcomes and Emergency Actions

The primary systems affected are the Central Nervous System and the Cardiovascular system. Severe, though rare, outcomes documented include cardiac arrest, circulatory collapse, and severe bradycardia. A specific hematological risk, Methemoglobinemia, is noted, particularly in neonates and infants following overdosage.

Regulatory authorities mandate that immediate medical attention be sought in the event of any suspected overdose, which includes contacting a poison control center or seeking emergency care. The medicine must be immediately discontinued upon the appearance of extrapyramidal symptoms or Methemoglobinemia.


Management and Monitoring

Overdose management is restricted to symptomatic and supportive treatment. Continuous monitoring of cardiovascular and respiratory functions is an essential requirement. The official labeling states that no specific antidote is known for Metoclopramide, though specific agents are used to manage complications, such as methylene blue for Methemoglobinemia. Symptoms are generally self-limiting, typically resolving within 24 hours.

Therapeutic Uses of Digestine

What Digestine Treats: Main Uses and Benefits

Digestine is used in areas where short-term symptom management is appropriate for symptoms related to physical discomfort in the upper abdomen.

Relieving Bloating and Upper Abdominal Fullness

This medicine is used for managing symptoms that interfere with daily functioning in the upper abdomen. This includes the uncomfortable sensation of bloating, pressure, and the feeling of being too full after eating. It contributes to improved comfort during periods of heightened symptoms.

Supporting Smoother Digestive Function

Digestine is commonly used to help with managing symptoms related to systemic imbalance in the digestive process. The medication assists with maintaining functional stability when symptoms create noticeable physiological strain. This supports patients during episodes of heightened discomfort and contributes to easing the overall symptom load.

Management of Episodic Digestive Upset

This medication is commonly used to help with managing symptoms that become more disruptive during flare-ups. Digestine may be part of symptomatic management and provides support that helps ease the overall symptom burden. It is applicable in conditions characterized by recurrent or episodic manifestations where short-term symptomatic assistance is needed.


Quick Fact: Symptom Management for Physical Discomfort

Digestine is commonly used to help with managing symptom clusters that may become more disruptive during flare-ups, contributing to improved comfort during periods of heightened symptoms.

Regulatory References

  1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Eligibility and Restrictions for Use

The eligibility profile for Digestine (Metoclopramide) is strictly defined by regulatory authorities, imposing mandatory exclusions to manage risks related to its effect on the gastrointestinal tract and the potential for neurological side effects.

Use of Digestine is Contraindicated for specific populations, including:

  • Infants under one year of age.
  • Patients with Parkinson's disease or a history of tardive dyskinesia from neuroleptics or metoclopramide.
  • Individuals with a confirmed or suspected pheochromocytoma or a history of epilepsy/seizure disorders.
  • Any patient with signs of gastrointestinal hemorrhage, mechanical obstruction, or perforation.

Use in Children and Adolescents (1–18 years) is highly restricted and only permitted as a second-line anti-emetic treatment for a maximum of five days due to increased neurological risks. Conditional Use is mandated for patients with severe renal or hepatic impairment, where official labeling requires a dose reduction based on organ function. Older adults also require special consideration and possible dose adjustment. Furthermore, use is generally not recommended for women who are breastfeeding due to potential infant exposure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes specific interaction patterns for Digestine (Metoclopramide) across pharmacokinetic and pharmacodynamic domains. Co-administration is formally prohibited with Levodopa and other Dopaminergic Agonists due to mutual antagonism that counteracts therapeutic effects. The co-administration of Digestine with other medicines known to cause Extrapyramidal Symptoms (EPS) is also strictly prohibited due to an increased risk of these reactions.

Documented Pharmacokinetic Interactions

Co-administration with strong CYP2D6 inhibitors (e.g., Fluoxetine, Quinidine) results in increased Metoclopramide plasma exposure due to reduced clearance, mandating a formal dose restriction. Digestine may also modify the absorption of other oral medications: it increases the bioavailability of Cyclosporine (formally documented by up to 46% for Cmax) and may decrease the bioavailability of Digoxin.

Pharmacodynamic Effects and Restrictions

An additive effect occurs with Central Nervous System (CNS) depressants, including Alcohol, which potentiates the sedative effect and must be avoided. Furthermore, there is an increased risk of Serotonin Syndrome when Digestine is combined with other serotonergic medicines. For patients with severe Renal or Hepatic Impairment, Metoclopramide clearance is reduced, which formally increases drug exposure and requires a mandated dosage restriction.

Mechanism of Action

Digestine acts as a mixed serotonin 5-HT4 receptor agonist and a dopamine D2 receptor antagonist, with additional serotonin 5-HT3 receptor antagonist properties at higher concentrations. The primary mechanism occurs peripherally within the gastrointestinal tract and centrally in the medulla's chemoreceptor trigger zone.

In the enteric nervous system, D2 receptor antagonism and 5-HT4 receptor agonism enhance the release of acetylcholine from enteric cholinergic neurons. This increase in cholinergic signaling elevates the tone of the lower esophageal sphincter and stimulates gastric and intestinal smooth muscle contraction. Intracellularly, 5-HT4 agonism is coupled to the adenylyl cyclase pathway, increasing cyclic AMP (cAMP) levels, which contributes to smooth muscle excitation. The combined action accelerates gastric emptying and intestinal transit. Centrally, D2 and 5-HT3 receptor antagonism in the chemoreceptor trigger zone blocks afferent signaling to the vomiting center, modulating the emetic reflex pathway. The overall system-level physiological consequence is the coordinated prokinetic modulation of upper gastrointestinal motility and central antiemetic action.

Dosage and Administration Information

Administration Instructions: How to Use Digestine

These instructions outline the administration method for Digestine.

Official Administration Protocol

Instruction Detail
Route of Administration Oral
Dosing Schedule Take one capsule daily
Timing in Relation to Meals Take with food
Age-Group Rule Restricted to adults (18 years and older)
Special Condition Capsule must be swallowed whole

Procedural Steps

The procedure for taking this medicine involves a clear sequence of steps:

  1. Check Eligibility: Confirm that the recipient is an adult (18 years or older), as use is not authorized for pediatric patients.
  2. Timing: Consume the medicine with a meal or snack to ensure correct absorption and compliance with instructions.
  3. Administration: Take one capsule and swallow it whole with a full glass of water. The capsule must not be chewed, crushed, or opened.

Missed Dose Instructions

If a daily dose is missed, instructions state to skip the missed dose entirely and proceed to take the next scheduled dose at the regularly appointed time. Patients must not take a double dose or more than one dose per day to compensate for a missed dose.

Structure of Official Use

This precise regimen—one capsule, taken orally and whole, daily, and with food—establishes the standardized and consistent usage protocol for the medicine. This structure defines the method of intake.

Recent Clinical Evidence

Research evidence / Overview of studies

This summary describes the primary findings reported in clinical research into the compound. This information is for informational purposes only and does not constitute medical advice or recommendations regarding treatment suitability.


Research Context

The compound is classified as an analgesic. Research has explored its use in relation to patient status.

Studies investigated the compound's behavior in the body. Research described the compound's half-life and bioavailability, with results suggesting consistent absorption across participants. Findings related to changes in pain severity were also reported, with some studies indicating a change.


Clinical Trial Findings

Efficacy and Pain Management

The majority of clinical evidence comes from Phase II and Phase III Randomised Controlled Trials (RCTs) involving patients with [INDICATION].

  • One large RCT evaluated the compound's impact on inflammation measures. The study measured primary outcomes using the [OUTCOME MEASURE 1] scale and secondary outcomes using the [OUTCOME MEASURE 2] scale.
  • A pooled analysis of three Phase III studies evaluated changes in reported pain levels and the time to onset of effect compared to placebo.
  • Studies investigated whether combining this compound with physiotherapy affected measures of mobility compared to physiotherapy alone.

Overall, the findings contribute to the body of evidence regarding chronic pain management.

Safety and Tolerability Profiles

The common side effects reported in the pooled safety data included [ADVERSE EVENT 1], [ADVERSE EVENT 2], and [ADVERSE EVENT 3]. Most adverse events were described as mild to moderate and did not require specific intervention per study protocol.

Safety and tolerability profiles were described in the research for people with mild-to-moderate symptoms. Research also included information regarding the study protocols for treatment discontinuation. The rates of discontinuation due to adverse events were [X]% in the treatment group compared to [Y]% in the placebo group.

Frequently Asked Questions (FAQ)

Common questions about Digestine (FAQ)


Q: How quickly should I expect Digestine to start having an effect?

A: According to the summary of clinical trials, relief of nausea is described as occurring early. Studies and official information indicate that symptoms continue to improve over a period of about three weeks after starting the treatment.


Q: Can Digestine interact with common over-the-counter pain relievers?

A: Regulatory information cautions against combining this medicine with other medications that cause central nervous system (CNS) depression, which means they can cause sleepiness or drowsiness. It also carries warnings about medicines with serotonergic effects. These categories may include certain medications often available over the counter.


Q: Is it okay to drink coffee or tea while using Digestine?

A: Official regulatory documents specifically caution against co-administration with alcohol because it is a CNS depressant. However, these documents do not provide specific warnings about the consumption of coffee or tea.


Q: If I miss a dose of Digestine, what is the usual recommendation?

A: Regulatory guidance indicates that a patient is instructed to skip the missed dose entirely and proceed to take the next scheduled dose at the regularly appointed time. Patients must not take a double dose to compensate.


Q: How long does Digestine typically stay in your system?

A: The elimination half-life for the active ingredient is typically described in official pharmacokinetics data as five to six hours in individuals with normal kidney function. This is the time it takes for half of the drug to be cleared from the system.


Q: What is the risk of an allergic reaction to Digestine?

A: Official regulatory information notes that the medicine is contraindicated, meaning it should not be used, in people with known allergies or hypersensitivity to any of its ingredients. If an individual is aware of an allergy to any ingredient, regulatory information indicates the product is contraindicated (should not be used).


Q: Are the long-term effects of Digestine usage well-documented?

A: Regulatory documents link the risk of a potentially serious movement disorder, Tardive Dyskinesia (TD), to the duration of treatment and the total cumulative dose. As a measure to manage this risk, the typical duration of use is formally restricted to a maximum of 12 weeks (3 months).


Q: Is Digestine used for stomach issues other than its main approved purpose?

A: The drug is officially indicated for the symptomatic treatment of conditions such as diabetic gastroparesis (delayed stomach emptying) and symptomatic gastroesophageal reflux disease (GERD), particularly when other treatments have failed. It is also used to prevent nausea and vomiting associated with certain medical procedures.


Q: Does Digestine need to be taken long-term?

A: Regulatory documents generally limit the use of this medicine to a maximum of 12 weeks in duration due to the increased risk of potentially serious neurological side effects with prolonged use. The typical course for some conditions may be shorter, often 2 to 8 weeks.


Q: Is there a generic version of Digestine available?

A: Yes, the active ingredient in Digestine is Metoclopramide. This active ingredient is available as a generic version.


Q: Are there any specific lifestyle changes that official documents suggest while taking Digestine?

A: Official documents advise that caution should be exercised when driving or operating machinery while taking this medicine due to the risk of drowsiness and other central nervous system effects that can impair motor skills and judgment.


Q: Has Digestine been studied in pregnant women or during breastfeeding?

A: Official information indicates that there is no evidence of harm to the baby from this medication in human studies, and the drug can be used during pregnancy. However, use while breastfeeding is generally not recommended or limited to short-term use because the active ingredient is known to pass into breast milk.


Q: Is it normal to feel a mild headache after starting Digestine?

A: According to the official safety profile, headache is an officially documented side effect. It is often listed among the most common adverse reactions reported in clinical trials.


Q: What is the typical timeframe for a treatment course of Digestine?

A: The maximum approved duration of use is 12 weeks. The typical length of treatment for conditions like diabetic gastroparesis is often described as 2 to 8 weeks until symptoms subside.


Q: Where can I find the official FDA/EMA patient information leaflet for Digestine?

A: The manufacturer's official patient information sheet (sometimes called a Medication Guide) is mandated to be provided by the pharmacist with each prescription and refill, as required by regulatory authorities.


Q: Is it common for Digestine to cause dry mouth or changes in taste?

A: Dry mouth (unusual dryness of the mouth) is listed as a possible side effect in regulatory documents. Changes in taste are also sometimes reported, particularly with certain dosage forms such as the nasal spray.


Q: If I feel better, can I stop taking Digestine?

A: Official information indicates that stopping this medicine should not be done abruptly. Withdrawal symptoms, such as dizziness, nervousness, and headaches, may occur if the medicine is stopped suddenly.


Q: Do people who take Digestine have to have regular blood tests?

A: Routine blood tests are typically not required for general use of the medicine. However, monitoring of kidney and liver function via blood tests is needed for patients with known or suspected impairment.


Q: Does Digestine have different instructions for different ages?

A: Yes, the official labeling includes different instructions and restrictions for use. Use is restricted to adults (18+) for the standard course, is highly restricted for children/adolescents (1-18 years), and requires special consideration for dose adjustment in older adults.


Q: Is Digestine known to affect sleep patterns?

A: The most common side effect is somnolence, which refers to drowsiness or sleepiness. Trouble sleeping (insomnia) is also listed in regulatory documents as a less frequent reported side effect.


Q: Does Digestine need special storage conditions?

A: Yes, official requirements state it must be stored at controlled room temperature, between 20 C and 25 C (68 F and 77 F). The product must be protected from moisture and must not be refrigerated or frozen.


Q: Why is Digestine sometimes used with other medications?

A: In acute clinical settings, the injectable form of the drug is sometimes administered with other medicines. This is done to help prevent nausea and vomiting associated with treatments like highly emetogenic chemotherapy (cancer treatment that causes strong vomiting).

How should Digestine be stored and disposed of?

How to Store and Dispose of Digestine?

Digestine must be stored according to official regulatory requirements to maintain its stability and effectiveness.

Storage Requirements

Storage Condition Requirement
Temperature Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F).
Protection Keep the product in its original, tightly closed container to protect it from moisture.
Handling Do not refrigerate or freeze the medication.
Safety Keep Digestine and all medicines out of the sight and reach of children.

Disposal

Official disposal guidance states that unused Digestine should not be flushed down a toilet or poured down a drain. To dispose of the product, use an authorized drug take-back program when available. If a take-back program is not accessible, mix the unused medication with an undesirable substance, place it in a sealed bag, and discard it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Digestine found in:

A-Z Index: